SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " formulation " 32 found 🔀 AI-powered Shuffle
Sign in to save shuffle history.
Particle Engineering and Formulation Science Drive the Next Wave of Drug Delivery
A forthcoming special issue of the Journal of Pharmaceutical Investigation will gather research on how particle engineering and formulation science are transforming drug solubility, dosage form design, and pharmaceutical manufacturing.
AI needs science’s search history
“Actually, that’s where the gold is,” said Alasdair Russell, my graduate school friend who leads a pre-clinical genome editing group at Cambridge. He was talking about the winding road of science that is omitted from published papers. “When you’re discussing how to do the experiment, and why this way is better than another way, and what does the data really mean? I know what it shows, but what does it mean?” At RAAIS 2026, he described how his group has begun logging the twisting path of discovery as it happens, recording the verbal and written exchanges that normally disappear. Ideas become nodes in a living graph: they branch when a meeting produces two plausible experiments, merge when separate lines of evidence converge, and go dark when someone quietly stops pursuing them. In his implementation, one agent scores novelty, while another tries to learn “how scientists think and how they navigate through a complex world of data,” so that high-potential nodes can trigger deeper investigation. As frontier AI labs deploy agents toward scientific discovery, giving AI authentic scientific taste remains a trillion-dollar dilemma. The bottleneck is that the record we have kept for centuries of science might be insufficient to get us there. The experiments that never make the paper Peter Medawar, 1960 Nobel laureate and “father of transplantation,” asked in 1963 whether the scientific paper was a fraud, and answered yes: the form of the paper misrepresents the thinking that produced it. Sixty years on, the diagnosis is unchanged. A paper presents a clean progression from hypothesis to result to conclusion. Lost along the way are the unconventional theories, the abandoned or unaffordable methods, and the underwhelming and inconclusive data. It reads like a browser history with every dead end deleted: the ten open tabs, the four rephrased queries, the wrong turn down a subforum. All scrubbed, leaving one clean path from question to answer as the canonical path. What has changed since then is that the discarded material is now worth something. No high-impact journal wants these artifacts, but raw trial and error is the most likely source of the training data required to develop scientific intuition, or what researchers call taste. Earlier attempts to capture the discards were motivated by scientific integrity. The Journal of Negative Results in Biomedicine launched in 2002 to publish rigorous studies that disputed established models or exposed ineffective treatments. Its archive preserved negative conclusions after they had become papers, rather than the live alternatives and arguments that produced them. BioMed Central closed it in 2017, saying the mission had been served now that other journals publish null results. A less generous reading is that in fifteen years it published around 200 papers because almost nobody wants to read a negative result, let alone write one up when it will not count toward academic tenure. AI models are different. Even an uninteresting negative result can be useful, provided it is labeled. Earlier this year, Anthropic put a version of this to the test. The company pulled 129 decision points from real Claude Code sessions between January and March 2026, showed models the work up to a human detour, and asked what should happen next. Claude Mythos Preview beat the human choice 64% of the time, while Opus 4.5 managed 51%. The comparison was tilted toward the models because Anthropic deliberately chose moments where the human decision had room for improvement. On 127 further scenarios where the human action was already strong, the models improved on it only about 20% of the time. The study was possible because Anthropic’s researchers work inside a tool that logs by default. The reasoning, detours and outcome are produced in the same working environment. Biology has no equivalent. Its reasoning happens in hallways, at benches, in Slack threads and on whiteboards, while the outcome arrives weeks later somewhere else. The record has to emerge from the work itself. Ask scientists to reconstruct it afterwards and we’ll create another polished account. Subscribe A log is not a label Before any of this becomes training data, a negative result has to say what failed. The first paper published in the Journal of Negative Results in Biomedicine examined 234 negative studies across five leading medical journals. Only 30% discussed statistical power, and half clearly defined a primary outcome. Tell a model an experiment failed, without telling it whether the assay was underpowered, a reagent had degraded, or the hypothesis was simply wrong, and it will learn noise with confidence. Decision histories have a second missing label too. When a lab considers five experiments and runs one, only the chosen branch returns an outcome. The other four are experimental counterfactuals. Researchers call this the selective labels problem: the data reveal results only for the actions someone chose to take. Such a record can teach a model to imitate a lab’s taste, but it cannot establish that the taste was good. It also smuggles local constraints into general lessons. A lab that never ran cryo-EM because it did not own a microscope teaches a model that cryo-EM is rarely the right call. Alasdair’s nodes preserve the candidate set, which is the necessary first step. To be useful, each decision record needs six fields: The evidence available at that moment, and nothing that arrived later. The candidates considered, including the ones dismissed in a sentence. For each candidate: the expected result, the confidence attached to it, and the cost in time and money. The route chosen, and the reason. What happened next. How the evidence changed the scientist’s view. These must be timestamped before the outcome, because hindsight turns uncertainty into inevitability. Disagreement also has to survive. Averaging three scientists into one clean rationale reproduces exactly the information loss we are trying to fix. But there is an obvious failure mode here. Once decisions are logged and scored, people log for the record post-facto. Anyone who has watched an electronic lab notebook fill up with retrospective tidying knows how quickly a research tool becomes a compliance exercise. A record that costs a scientist ten minutes of honest reflection per decision is worth far more than one that costs an hour of performance. A publication initiative called Registered Reports offers a useful starting point. Here, researchers submit their rationale, methods and analysis plan for peer review before the data exist, and the journal commits in principle to publish if they follow the approved plan. Nature has now expanded the format across every field it covers. This approach to paper writing timestamps intent before the outcome, but it freezes one plan. A useful search history must also preserve how the plan changed, which alternatives were rejected, when, and on what evidence. Subscribe Run the runner-up Autonomous labs show what happens when decisions and outcomes are connected in a loop. Liverpool’s mobile robotic chemist ran 688 experiments over eight days in a ten-variable formulation space. A batched Bayesian search used each result to choose the next experiments and found photocatalyst mixtures six times more active than the starting formulations. Every completed experiment changed what the system did next. The robot optimized within a goal and search space that humans had already chosen. It did not decide which scientific question mattered. So what this work demonstrates is narrower, but still useful: a search history pays off when the options return standardized outcomes quickly. Open-ended biology is harder because branches can take weeks and the discarded alternatives may never be run. Some exploration therefore has to be bought. Where two branches are plausible and the stakes justify the cost, a lab should sometimes run the runner-up. Otherwise the record captures what today’s scientists usually chose and stays silent on what they systematically overlooked. A funder could ring-fence a small fraction of a grant for the branch not taken, provided that the decision record and the outcome are both deposited. That costs money, but so does having every lab rediscover the same abandoned path. Test whether taste transfers When it comes time to evaluate if our new AI system exhibits taste, the comparison should run across laboratories and fields. At selected decision points in a live research campaign, we should freeze the six fields: the evidence, the candidates, expected results, confidence, costs and the choice made. Experts then rank the options before the outcomes are known, and those outcomes are checked independently later. We could give models one of two diets - papers alone, or papers plus decision histories - and ask them to rank the next experiment on unfamiliar projects. Then, we score information gained per dollar and week, calibration, and how quickly weak branches are abandoned. If histories improve choices only inside the lab that produced them, they amount to useful organizational memory. If they improve choices on unfamiliar problems elsewhere, Alasdair’s group will have captured something science has never managed to write down: a transferable record of taste. Until that happens, a scientific search history is a promising record, not yet a training set.
ProBiotix Health targets long-term women’s health beyond menopause symptom support
Women’s health research is growing, and scientists are learning that supporting consumers through menopause means going beyond addressing symptoms. Cellan Davies, head of marketing at ProBiotix Health, tells Nutrition Insight which menopause-support ingredients and formulation approaches are gaining the most traction within women’s health.
Virginia Dare expands sensory and health & wellness teams
The US flavour specialist will showcase functional food, beverage and supplement concepts at SupplySide Global, highlighting its expanded capabilities in sensory testing, formulation and wellness-focused product development
Amendment 79: New Opportunity: B.8 Heliophysics Spaceflight Science Foundations
The Heliophysics Spaceflight Science Foundations (SSF) program (B.8 of ROSES) solicits investigations that enable the formulation of high-impact spaceflight
New formulation helps RNA vaccines withstand high temperatures
MIT researchers used artificial intelligence to create more stable, heat-resistant RNA vaccines.
Artificial sweeteners: Why the science war is raging on
Conflicting studies on artificial sweeteners are fuelling fresh debate across food and drink, as health risks, regulation and reformulation collide worldwide.
Chance discovery boosts the efficiency of perovskite tandem solar cells
Controlling the additive concentration gradient in mixed-halide perovskite formulations affects how well they perform as solar cells.
Particle Engineering Takes Center Stage as Formulation Science Pushes Drugs Toward the Clinic
A January 2027 special issue of the Journal of Pharmaceutical Investigation will spotlight how particle engineering and formulation science translate laboratory innovations into manufacturable drug dosage forms.
Fera Pets Launches Science-Backed Pet Supplements Into Petco End Caps Nationwide
Fera Pets, the premium veterinarian-founded pet wellness brand known for its science-driven formulations and rigorous quality standards, is expanding into Petco stores nationwide, bringing its clinically-formulated supplements to pet parents in a leading brick-and-mortar retail destination within the space.
Will P&G’s (PG) New Science-Led Head & Shoulders and Oral-B iO Push Change Its Narrative?
In recent months, Procter & Gamble has rolled out new Head & Shoulders formulations featuring the HydraZinc Complex and expanded its Oral-B iO line, emphasizing clinically tested scalp and oral care technologies now available across multiple product collections in the U.S. market. These launches highlight how Procter & Gamble is leaning on science-led product innovation to reinforce its brands and support its broader shift from pricing-driven growth toward offering more tangible consumer...
Pelican Unveils Next-Generation Protector Cases with Advanced HPX Polymer Science & Modular Accessories
Pelican Products recently launched its Next Generation Protector series, upgrading its namesake case line with advanced polymer formulations and modular...
Science-Backed Beauty Formulations Market Size and Growth Analysis Study 2026 to 2035
Global Science-Backed Beauty Formulations Market Size is predicted to grow at a 8.6% CAGR during the forecast period for 2026 to 2035. The skincare formulations segment is set to take a large share of the science-backed beauty market. This growth comes from more people focusing on skin health, anti-ageing, acne, hyperpigmentation, and barrier repair.
Ennature Biopharma Advances Women’s Health Science With Fast-Acting Shatavari and Sustained-Release Ginger
NOIDA, India, Sept. 16, 2026 (GLOBE NEWSWIRE) -- Ennature Biopharma is expanding the clinical evidence for its Aspargize and Gingeren botanical ingredients, addressing two distinct areas of women’s health: menopause and menstrual health. The botanical formulations pair Shatavari for menopausal support with sustained-release ginger for menstrual comfort. The findings come amid growing interest in evidence-based women’s health solutions and ahead of World Menopause Month and SupplySide Global in O
Particle Engineering and Formulation Science Drive the Next Generation of Drug Delivery
The Journal of Pharmaceutical Investigation has announced a January 2027 special issue on translational advances in pharmaceutical dosage form development driven by particle engineering and formulation science.
AAPS names Patrick Sinko chief science officer
Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation.
Croma Skincare – Where Science Meets Skin
LEOBENDORF, Austria, May 26, 2026--With Croma Skincare, Austrian family-owned company Croma Pharma translates decades of expertise in aesthetic medicine into a modern skincare line designed for everyday results. Rather than following short-lived trends, Croma focuses on scientifically proven ingredients and pharmaceutical-grade formulations that deliver visible performance while fitting seamlessly into daily routines.
Experts Debate How MAHA Is Reshaping Food Science and Regulation
Experts at IFT FIRST examined how the MAHA movement is influencing food regulation, ingredient reformulation, consumer expectations, and food science.
Formulated with authority: Separating science from marketing in vet-formulated products
Vet related claims must go beyond pet food product labels into R&D and formulation.
Why Circulation Health Supplements Are Gaining Attention for Supporting Healthy Vascular Function and Everyday Wellness, According to PureHealth Research
PureHealth Research is highlighting growing consumer interest in circulation wellness and the role of targeted nutritional supplementation in maintaining healthy blood flow, vascular function, and overall cardiovascular wellness.Circulation health supplements commonly feature ingredients such as Omega-3 Fatty Acids, Berberine and Butcher's Broom, which are frequently included in formulations designed to promote healthy circulation and vascular health.
SK Life Science, Inc. Announces FDA Acceptance for Review of New Drug Application for Cenobamate Oral Suspension
Key Facts: FDA has accepted for review the New Drug Application (NDA) for an investigational oral suspension formulation of cenobamate for the treatment of...
Ingredion plans global Benicaros prebiotic expansion across gut and immune health applications
Ingredion highlights that its recent acquisition of the Benicaros prebiotic is a strong strategic addition to its Healthful Solutions portfolio, supporting the company’s formulation versatility alongside expansion of health-forward and clean label ingredients. The company purchased the patented prebiotic fiber, made from upcycled carrot pomace, from NutriLeads earlier this month. With the deal, Ingredion obtained full ownership of all intellectual property, trademarks, human clinical trials, and know-how related to manufacturing Benicaros.
Particle Engineering Takes Center Stage in Push to Translate Drug Formulation Science
The Journal of Pharmaceutical Investigation has announced a January 2027 special issue on translational advances in pharmaceutical dosage form development driven by particle engineering and formulation science, with submissions due by June 30, 2026.
Rocket Science Health validates targeted olfactory-cleft deposition in non-human primates ahead of the 4th Nasal Formulation & Delivery Summit
As the pace of modern drug discovery accelerates, the industry is increasingly recognizing that a breakthrough molecule is only as effective as its ability to reach the target site.
Can HRT help prevent dementia? New research suggests it might
As debate continues over whether hormone replacement therapy can protect against dementia, new studies suggest timing and formulation are key.
Particle Engineering Takes Center Stage as Journal Puts Drug Formulation Science in the Spotlight
The Journal of Pharmaceutical Investigation has announced a January 2027 special issue on translational particle engineering and formulation science, with submissions due June 30, 2026.
Particle Engineering Takes Center Stage as Pharma Formulation Science Pushes Toward the Clinic
A forthcoming special issue of the Journal of Pharmaceutical Investigation will spotlight how particle engineering and formulation science are turning poorly soluble drug candidates into manufacturable medicines.
RosCept Capsules Introduces Ros Cept Multi-Ingredient Dietary Supplement for Brain Health, Memory and Concentration
RosCept dietary supplement features Magnesium Beta Hydroxybutyrate, Calcium Beta Hydroxybutyrate, and Sodium Beta Hydroxybutyrate in a focused BHB formulation.Wilmington, DE, Oct. 05, 2026 (GLOBE NEWSWIRE) -- RosCept has announced the introduction of RosCept, a multi-ingredient dietary supplement formulated with three mineral beta-hydroxybutyrate (BHB) compounds: Magnesium Beta Hydroxybutyrate, Calcium Beta Hydroxybutyrate, and Sodium Beta Hydroxybutyrate. Official Website: https://roscept.shop/
Particle Engineering Takes Center Stage as Drug Formulation Science Enters Its Translational Era
The Journal of Pharmaceutical Investigation has announced a January 2027 special issue on translational advances in pharmaceutical dosage form development, covering particle engineering, solid-state control, QbD, and emerging manufacturing technologies, with submissions due June
Bausch Health’s $2B pursuit of Xifaxan successor hits wall with phase 3 failure
A potential inflection point that Bausch Health hoped could diversify its portfolio has vanished with a pair of phase 3 failures for a new formulation of the company’s bread-and-butter Xifaxan—a se | A potential inflection point that Bausch Health hoped could diversify its portfolio has vanished with a pair of phase 3 failures for a new formulation of the company’s bread-and-butter Xifaxan—a setback that leaves a $2 billion hole in its growth plan.
AAPS PharmSci 360 Offers Fresh Insights for Industry Scientists
Drug Discovery and Development covers strategies and technologies related to pharmaceutical research and development and drug formulation.
Solésence Brings Patent-Backed Skin Health Innovation to Hair and Scalp
New White Label Collection, Powered by WHSPR™ and Kleair™, Debuts with Revitalizing Scalp Serum and Scalp Screen Dry Shampoo SPF 45+ Sunscreen Scalp Screen Dry Shampoo SPF 45+ Sunscreen Named a Finalist for the 2026 Cosmopack Award for Best Formulation at Cosmoprof Las Vegas ROMEOVILLE, Ill., July 13, 2026 (GLOBE NEWSWIRE) -- Solésence, Inc. (Nasdaq: SLSN), a leader in scientifically-driven health care solutions across beauty and life science categories, today announced the launch of two new mar